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tors such as toxicity and cost need to be considered.
With the current chelation regimen, the balance between
iron accumulation and excretion is fine.1,6,10 In contrast to the
iron balance achieved by monotherapy with either DFP or DFO,
iron balance achieved with combined therapy was negative in
the majority of patients.
In conclusion, combined therapy with DFO and DFP showed
an additive and occasionally synergistic effect on UIE, which
could reach levels higher than iron accumulation from trans-
fusions, leading to a negative iron balance. Long-term studies
are required to validate the efficacy and safety of combined
therapy.
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Lack of Bcr-Abl point mutations in chronic myeloid
leukemia patients in chronic phase before imatinib
treatment is not predictive of response 
We describe the presence of abl point mutations detected
using a highly sensitive technique in 5 out of 9 patients with
chronic phase CML resistant to imatinib. These mutations
were not detected in samples obtained before initiating ther-
apy with imatinib. Unless more sensitive techniques are
developed, the presence or absence of point mutations before
starting imatinib therapy will not help in predicting respons-
es to treatment.haematologica 2003; 88:1425-1426
(http://www.haematologica.org/2003_12/1425.htm)
Despite the positive results of treatment with imatinib mesy-
late (IM) in patients with chronic myelogenous leukemia (CML)1
a number of patients develop clinical resistance to this drug,
resulting in progression of the disease at 18 months in 11% of
interferon resistant/intolerant patients.2 Most patients in blast
crisis will eventually suffer disease progression despite contin-
uous treatment with imatinib.3,4
Among the different mechanisms of  in vivo resistance to IM,
the most frequently detected in patients with advanced phase
(accelerated or blast crisis) CML is point mutations in the kinase
domain of Abl.5-7 We studied the presence of Bcr-Abl muta-
tions in a homogeneous group of CML patients in chronic phase
with primary cytogenetic resistance to IM in order to deter-
mine the incidence of point mutations and whether the pres-
ence of these substitutions before treatment could predict resis-
tance to IM therapy. 
We studied a group of 89 patients with CML enrolled in an
extended access trial of IM (chronic phase CML patients resis-
tant to or intolerant of interferon-α). All patients had 100%
Philadelphia positive metaphases. Patients with no cytogenet-
ic response after at least 6 months of therapy were defined as
having primary resistance to IM and analyzed for the presence
of Abl mutations. Bone marrow mononuclear cells were
obtained before initiating treatment with IM and every 3
months thereafter.
Total RNA was extracted using RNeasy®Mini Kit (Qiagen,
Hilden, Germany) from frozen cells. Total RNA (1 µg) was used
for cDNA synthesis using SuperScript™ II RNase H-RT (Invitro-
gen Life Technologies, Paisley, UK) with random hexamers. A
BCR-ABL transcript of 1.3 kb was amplified by PCR using 4 µL
of cDNA and CM10 (5´-GAAGCTTCTCCCTGACATCCGT-3´) and
3ABL2 (5´-CGGACTTGATGGAGAACTTG-3´) primers under the
following conditions: 94°C for 10 min, 30 cycles at 94°C for 30
seconds, 58°C for 30 seconds and 72°C for 90 seconds, and a
final elongation cycle at 72ºC for 10 min. The Abl kinase domain
was amplified in a second PCR using 1 µL of the first PCR prod-
uct and 5ABLKD (5´-GCGCAACAAGCCCACTGTCTATGG-3´) and
3ABLKD (5´-GCCAGGCTCTCGGGTGCAGTCC-3´) primers with the
following conditions: 94°C for 10 min, 30 cycles at 94°C for30
seconds, 70°C for 30 seconds and 72°C for 30 seconds, followed
by an elongation cycle at 72°C for 10 min. All PCR reactions
were carried out in a total volume of 25 µL, with 2.5 U of native
PFU polymerase (Stratagene, Amsterdam, The Netherlands), 0.4
mM dNTPs and 20 pmol of each primer.
The second PCR product (597 bp) was subcloned into pCR® 4-
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TOPO® plasmid using TOPO TA Cloning® Kit for Sequencing (Invit-
rogen Life Technologies, Paisley, UK). Ten  colonies with recombi-
nant plasmid containing the 597 bp PCR product were sequenced
using T7 and T3 universal forward and reverse primers. Only sub-
stitutions present in at least 2 clones were considered as mutations
in accordance with Shah et al.6
Nine of 89 patients showed complete cytogenetic resistance to
IM (100% Ph positive metaphases after more than 6 months of
treatment) despite having a complete hematologic response. No
BCR-ABL gene amplification was detected by fluorescent in situ
hybridization analysis at the time of resistance in any of our
patients (data not shown) suggesting that this mechanism is rarely
the cause of resistance in patients with CML in chronic phase.
Mutations of the Abl kinase domain were identified in 5 patients
after treatment with IM (Table 1). The detected substitutions cor-
respond to previously described mutations that conferred resis-
tance to IM. The G250E and M244V mutations, located in the ATP
phosphate binding loop (P loop), and M351T, located in the C-ter-
minal loop of the kinase, confer resistance due to changes in the
conformation of the kinase domain which prevent it from binding
IM. The F359V mutation is located at sites that are in direct con-
tact with IM, impairing binding of the drug without affecting bind-
ing of ATP. 
The current hypothesis is that mutations within the Abl gene
are induced throughout the course of the disease and that treat-
ment with IM selects for these clones. Our study was initially
designed to try to determine whether detection of point mutations
in patients with chronic phase CML could predict response to IM.
Unlike other studies6,8 we were not able to detect mutations in
samples obtained before treatment with IM. Different techniques
for detecting point mutations have different sensitivities. Direct
sequencing can only detect mutations when most of the clones
harbor the substitution. By subcloning and sequencing multiple
independent clones we can detect mutant clones when these rep-
resent about 20% of the total Bcr-Abl positive cell population.6
Allele-specific oligonucleotide PCR may detect mutations even
when less than 20% of the cells are mutated, however it can only
be applied to specific substitutions and requires different primers
to be designed for each mutation.8 The fact that we analyzed a
group of patients in chronic phase, who are less likely to harbor
mutations than patients in advanced phase, may also explain dif-
ferences between our results and those of previous studies.6,8
In a small group of patients, samples were analyzed in duplicate
using 2 different Taq polymerases with or without proofreading
activity. Interestingly, the use of a Taq polymerase without proof-
reading activity detected multiple substitutions present in single
clones, some of which have been described as mutations in patients
with resistance to IM. None of these substitutions was found when
Taq polymerase with proofreading activity was employed suggest-
ing that these were artifacts introduced in the PCR reaction (data
not shown).
In 4 patients, the 700 bp region 5’ to the kinase domain was
sequenced using the same approach. No evidence of additional
mutations could be found in these patients either before or after
treatment with IM. These findings are in agreement with those of
previous studies6 and suggest that there is no global increase in
mutation frequency and further support the hypothesis that only
mutations associated with an IM-resistant phenotype would be
selected.  
In conclusion, by subcloning and sequencing multiple clones we
detected point mutations in the kinase domain of Bcr-Abl in more
than 50% of  chronic phase CML patients with primary cytogenet-
ic resistance to IM indicating for the first time that this mechanism
of resistance to IM is highly prevalent also in chronic phase CML.
The fact that no mutations were found in samples obtained before
IM treatment suggest that unless more sensitive techniques can be
developed, the presence or absence of mutations will not help to
predict resistance to IM.
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Table 1. BCR-ABL kinase domain mutations detect-
ed in 5 CML patients.
Nucleotide Nucleotide Amino acid Mutant
substitution substitution clones
CML 1 749 G→A G250E (Gl→Glu) 8/10
CML 2 749 G→A G250E (Gly→Glu) 10/10
CML 3 730 A→G M244V (Met→Val) 4/10
1052 T→C M351T (Met→Thr) 5/10
CML 4 1075 T→G F359V (Phe→Val) 10/10
CML 5 1075 T→G F359V (Phe→Val) 10/10
